These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12971645)

  • 21. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".
    Higashi T; Saga T; Nakamoto Y; Ishimori T; Fujimoto K; Doi R; Imamura M; Konishi J
    Ann Nucl Med; 2003 Jun; 17(4):261-79. PubMed ID: 12932109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.
    Boykin KN; Zibari GB; Lilien DL; McMillan RW; Aultman DF; McDonald JC
    Am Surg; 1999 Dec; 65(12):1183-5. PubMed ID: 10597072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
    Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
    World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET).
    Mantaka P; Strauss AD; Strauss LG; Moehler M; Goldschmidt H; Oberdorfer F; Kontaxakis G; Van Kaick G
    Anticancer Res; 1999; 19(5C):4443-50. PubMed ID: 10650790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed therapy.
    Wong CY; Gates VL; Tang B; Campbell J; Qing F; Lewandowski RJ; Thie J; Ho CL; Savin M; Salem R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):233-6. PubMed ID: 20423237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.
    Francis DL; Visvikis D; Costa DC; Arulampalam TH; Townsend C; Luthra SK; Taylor I; Ell PJ
    Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):988-94. PubMed ID: 12739071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
    Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
    J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of benign vs malignant hepatic lesions with positron emission tomography.
    Delbeke D; Martin WH; Sandler MP; Chapman WC; Wright JK; Pinson CW
    Arch Surg; 1998 May; 133(5):510-5; discussion 515-6. PubMed ID: 9605913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
    Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
    Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
    Zimny M; Schumpelick V
    Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer.
    Rohren EM; Paulson EK; Hagge R; Wong TZ; Killius J; Clavien PA; Nelson RC
    Clin Nucl Med; 2002 Aug; 27(8):550-5. PubMed ID: 12169999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer.
    Khan N; Oriuchi N; Yoshizaki A; Kanuma T; Higuchi T; Endo K
    Ann Nucl Med; 2005 Apr; 19(2):137-45. PubMed ID: 15909494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
    Ak I; Sivrikoz MC; Entok E; Vardareli E
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors.
    Kitajima K; Nakamoto Y; Okizuka H; Onishi Y; Senda M; Suganuma N; Sugimura K
    Ann Nucl Med; 2008 Aug; 22(7):595-602. PubMed ID: 18756362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.